Cargando…
Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the un...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782520/ https://www.ncbi.nlm.nih.gov/pubmed/24083081 http://dx.doi.org/10.4161/onci.25409 |